News and features

Combining a genetically targeted drug, a cancer-bursting virus and a drug that removes the immune system’s brake pedal can tackle thyroid cancer with newfound gusto, research has found.

We've selected a range of discoveries from 2019/20 – chosen because they illustrate the quality and breadth of our basic, translational and clinical research and our ambitions under the ICR's research strategy.

We celebrate the festive season and our world-leading research, with a special virtual Carols from Chelsea concert. For the past 17 years, our flagship annual social and fundraising event has been held at The Royal Hospital Chelsea, but is now shared online for the very first time.

A survey of more than 200 researchers details impact of the pandemic. The scientists estimate their own research has been put back by six months through loss of access to labs, facilities, trials and samples. But they feel science has now adapted to COVID-19 – and researchers believe donations and Government support could accelerate recovery.

A blood test to watch breast cancer’s ‘molecular clock’ could help track the growth of multiple tumours around the body and monitor how they are responding to treatment, new research suggests.

Cancer researchers talk about their pioneering work to discover and develop new drugs in a new video for schools and students designed to bring the GCSE curriculum on the creation of new treatments to life.

A world-first new centre aiming to overcome cancer’s ability to evolve and become resistant to once effective treatments has opened its doors to researchers. Scientists at the new Centre for Cancer Drug Discovery hope their approaches will mean long-term control of cancer, as well as cures.

A simple and inexpensive blood test could pick out patients with stomach or oesophageal cancer who are likely to benefit from targeted treatment, a new study shows.

Street artist James Cochran has created a 50,000-dot painting using a lab pipette – to illustrate pioneering new research which will be undertaken in the ICR's new Centre for Cancer Drug Discovery.

The NHS could improve patients’ access to new cancer treatments by paying different prices for drugs depending on the disease they are used to treat, concludes a group of experts from across academia and industry.

The Institute of Cancer Research, London, has strongly welcomed the approval by the European Commission of the targeted drug olaparib for men with advanced prostate cancers with genetic alterations in BRCA1 or BRCA2.

Scientists at The Institute of Cancer Research, London, have developed a complex model system that mimics the most common form of bowel cancer and is showing how it ‘hides’ from immunotherapy.